These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22752396)

  • 1. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
    Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
    Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
    Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
    Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
    Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
    Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
    BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
    Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
    Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
    McCullough PA; Barnhart HX; Inrig JK; Reddan D; Sapp S; Patel UD; Singh AK; Szczech LA; Califf RM
    Am J Nephrol; 2013; 37(6):549-58. PubMed ID: 23735819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
    Kuragano T; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Kitamura K; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura I; Nakanishi T
    Kidney Int; 2014 Oct; 86(4):845-54. PubMed ID: 24759150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
    Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
    Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
    Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
    Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
    Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.